{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:08:56Z","timestamp":1784167736869,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11864-023-01156-2","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T11:02:08Z","timestamp":1706785328000},"page":"261-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma"],"prefix":"10.1007","volume":"25","author":[{"given":"David","family":"Gritsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"1156_CR1","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/1097-0142(197604)37:4<1944::AID-CNCR2820370446>3.0.CO;2-#","volume":"37","author":"CK Petito","year":"1976","unstructured":"Petito CK, DeGirolami U, Earle KM. Craniopharyngiomas: a clinical and pathological review. Cancer. 1976;37:1944\u201352.","journal-title":"Cancer"},{"key":"1156_CR2","doi-asserted-by":"crossref","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020. Neuro Oncol. 2023;25:iv1\u2013iv99.","DOI":"10.1093\/neuonc\/noad149"},{"key":"1156_CR3","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/S0002-9440(10)64477-X","volume":"161","author":"S Sekine","year":"2002","unstructured":"Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, Sakamoto M, Hirohashi S. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol. 2002;161:1997\u20132001.","journal-title":"Am J Pathol"},{"key":"1156_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46:161\u20135.","journal-title":"Nat Genet"},{"key":"1156_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00401-005-1004-x","volume":"109","author":"R Buslei","year":"2005","unstructured":"Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnr\u00fcbl F, Hahnen E, Kreutzer J, Fahlbusch R. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol. 2005;109:589\u201397.","journal-title":"Acta Neuropathol"},{"key":"1156_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1159\/000504512","volume":"110","author":"HL M\u00fcller","year":"2020","unstructured":"M\u00fcller HL. The diagnosis and treatment of craniopharyngioma. Neuroendocrinology. 2020;110:753\u201366.","journal-title":"Neuroendocrinology"},{"key":"1156_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11102-021-01127-6","volume":"24","author":"AA Momin","year":"2021","unstructured":"Momin AA, Recinos MA, Cioffi G, Patil N, Soni P, Almeida JP, Kruchko C, Barnholtz-Sloan JS, Recinos PF, Kshettry VR. Descriptive epidemiology of craniopharyngiomas in the United States. Pituitary. 2021;24:517\u201322.","journal-title":"Pituitary"},{"key":"1156_CR8","doi-asserted-by":"crossref","unstructured":"Larkin S, Karavitaki N. Recent advances in molecular pathology of craniopharyngioma. F1000Res 2017;6:1202.","DOI":"10.12688\/f1000research.11549.1"},{"key":"1156_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","volume":"4","author":"A H\u00f6lsken","year":"2016","unstructured":"H\u00f6lsken A, Sill M, Merkle J, et al. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun. 2016;4:20.","journal-title":"Acta Neuropathol Commun"},{"key":"1156_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1750-3639.2008.00180.x","volume":"19","author":"A H\u00f6lsken","year":"2009","unstructured":"H\u00f6lsken A, Kreutzer J, Hofmann BM, Hans V, Oppel F, Buchfelder M, Fahlbusch R, Bl\u00fcmcke I, Buslei R. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas. Brain Pathol. 2009;19:357\u201364.","journal-title":"Brain Pathol"},{"key":"1156_CR11","first-page":"173","volume":"3","author":"J Varlotto","year":"2016","unstructured":"Varlotto J, DiMaio C, Grassberger C, et al. Multi-modality management of craniopharyngioma: a review of various treatments and their outcomes. Neurooncol Pract. 2016;3:173\u201387.","journal-title":"Neurooncol Pract"},{"key":"1156_CR12","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3390\/curroncol29030138","volume":"29","author":"M Lara-Velazquez","year":"2022","unstructured":"Lara-Velazquez M, Mehkri Y, Panther E, Hernandez J, Rao D, Fiester P, Makary R, Rutenberg M, Tavanaiepour D, Rahmathulla G. Current advances in the management of adult craniopharyngiomas. Curr Oncol. 2022;29:1645\u201371.","journal-title":"Curr Oncol"},{"key":"1156_CR13","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2010.1.FOCUS09297","volume":"28","author":"EN Kiehna","year":"2010","unstructured":"Kiehna EN, Merchant TE. Radiation therapy for pediatric craniopharyngioma. Neurosurg Focus. 2010;28:E10.","journal-title":"Neurosurg Focus"},{"key":"1156_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3171\/jns.1999.90.2.0251","volume":"90","author":"J Honegger","year":"1999","unstructured":"Honegger J, Buchfelder M, Fahlbusch R. Surgical treatment of craniopharyngiomas: endocrinological results. J Neurosurg. 1999;90:251\u20137.","journal-title":"J Neurosurg"},{"key":"1156_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/pbc.21787","volume":"52","author":"AK Liu","year":"2009","unstructured":"Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK. Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer. 2009;52:227\u201330.","journal-title":"Pediatr Blood Cancer"},{"key":"1156_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pediatrneurol.2013.09.003","volume":"50","author":"A Rosenfeld","year":"2014","unstructured":"Rosenfeld A, Arrington D, Miller J, Olson M, Gieseking A, Etzl M, Harel B, Schembri A, Kaplan A. A review of childhood and adolescent craniopharyngiomas with particular attention to hypothalamic obesity. Pediatr Neurol. 2014;50:4\u201310.","journal-title":"Pediatr Neurol"},{"key":"1156_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11060-010-0265-y","volume":"101","author":"ME Sughrue","year":"2011","unstructured":"Sughrue ME, Yang I, Kane AJ, Fang S, Clark AJ, Aranda D, Barani IJ, Parsa AT. Endocrinologic, neurologic, and visual morbidity after treatment for craniopharyngioma. J Neurooncol. 2011;101:463\u201376.","journal-title":"J Neurooncol"},{"key":"1156_CR18","doi-asserted-by":"crossref","unstructured":"Zhang S, Fang Y, Cai BW, Xu JG, You C. Intracystic bleomycin for cystic craniopharyngiomas in children. Cochrane Database Syst Rev. 2016;7:CD008890.","DOI":"10.1002\/14651858.CD008890.pub4"},{"key":"1156_CR19","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2010.1.FOCUS09310","volume":"28","author":"S Cavalheiro","year":"2010","unstructured":"Cavalheiro S, Di Rocco C, Valenzuela S, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus. 2010;28:E12.","journal-title":"Neurosurg Focus"},{"key":"1156_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00381-005-1226-1","volume":"21","author":"S Cavalheiro","year":"2005","unstructured":"Cavalheiro S, Dastoli PA, Silva NS, Toledo S, Lederman H, da Silva MC. Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv Syst. 2005;21:719\u201324.","journal-title":"Childs Nerv Syst"},{"key":"1156_CR21","unstructured":"\u2022\u2022 Brastianos PK, Twohy E, Geyer S, et al. BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas. N Engl J Med. 2023;389:118\u2013126. The study demonstrated the effectiveness of BRAF\/MEK inhibition with vemurafenib\u2013cobimetinib in the treatment of BRAF V600E mutated papillary craniopharyngiomas."},{"key":"1156_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809\u201319.","journal-title":"N Engl J Med"},{"key":"1156_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad205","author":"S Coy","year":"2023","unstructured":"Coy S, Lee JS, Chan SJ, Woo T, Jones J, Alexandrescu S, Wen PY, Sorger PK, Ligon KL, Santagata S. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol. 2023. https:\/\/doi.org\/10.1093\/neuonc\/noad205.","journal-title":"Neuro Oncol"},{"key":"1156_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0360-3016(03)01570-0","volume":"58","author":"DCH Stripp","year":"2004","unstructured":"Stripp DCH, Maity A, Janss AJ, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys. 2004;58:714\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1156_CR25","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.3171\/2010.1.FOCUS09307","volume":"28","author":"I Yang","year":"2010","unstructured":"Yang I, Sughrue ME, Rutkowski MJ, Kaur R, Ivan ME, Aranda D, Barani IJ, Parsa AT. Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus. 2010;28:E5.","journal-title":"Neurosurg Focus"},{"key":"1156_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.nrl.0000144287.35993.96","volume":"10","author":"PK Duffner","year":"2004","unstructured":"Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004;10:293\u2013310.","journal-title":"Neurologist"},{"key":"1156_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11060-014-1476-4","volume":"119","author":"LM Jacola","year":"2014","unstructured":"Jacola LM, Ashford JM, Reddick WE, Glass JO, Ogg RJ, Merchant TE, Conklin HM. The relationship between working memory and cerebral white matter volume in survivors of childhood brain tumors treated with conformal radiation therapy. J Neurooncol. 2014;119:197\u2013205.","journal-title":"J Neurooncol"},{"key":"1156_CR28","doi-asserted-by":"crossref","unstructured":"\u2022 Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23:53\u201364. The study showed that combined BRAF\/MEK inhibition with dabrafenib and trametinib is effective in treating BRAF V600E mutation-positive high-grade and low-grade gliomas.","DOI":"10.1016\/S1470-2045(21)00578-7"},{"key":"1156_CR29","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694\u2013703.","journal-title":"N Engl J Med"},{"key":"1156_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18:863\u201373.","journal-title":"Lancet Oncol"},{"key":"1156_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang X. Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13:165.","journal-title":"J Hematol Oncol"},{"key":"1156_CR32","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","volume":"135","author":"JR Apps","year":"2018","unstructured":"Apps JR, Carreno G, Gonzalez-Meljem JM, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target. Acta Neuropathol. 2018;135:757\u201377.","journal-title":"Acta Neuropathol"},{"key":"1156_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28753","volume":"68","author":"K Patel","year":"2021","unstructured":"Patel K, Allen J, Zagzag D, Wisoff J, Radmanesh A, Gindin T, Nicolaides T. Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma. Pediatr Blood Cancer. 2021;68: e28753.","journal-title":"Pediatr Blood Cancer"},{"key":"1156_CR34","doi-asserted-by":"crossref","unstructured":"Lober RM, Harsh GR 4th. A perspective on craniopharyngioma. World Neurosurg. 2013;79:645\u2013646.","DOI":"10.1016\/j.wneu.2012.10.064"},{"key":"1156_CR35","doi-asserted-by":"crossref","unstructured":"Duff J, Meyer FB, Ilstrup DM, Laws ER Jr, Schleck CD, Scheithauer BW. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000;46:291\u2013302; discussion 302\u20135.","DOI":"10.1097\/00006123-200002000-00007"},{"issue":"Suppl 1","key":"1156_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000120859","volume":"21","author":"WH Sweet","year":"1994","unstructured":"Sweet WH. History of surgery for craniopharyngiomas. Pediatr Neurosurg. 1994;21(Suppl 1):28\u201338.","journal-title":"Pediatr Neurosurg"},{"key":"1156_CR37","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hed.21771","volume":"34","author":"JC Fernandez-Miranda","year":"2012","unstructured":"Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Strojan P, Su\u00e1rez C, Genden EM, Rinaldo A, Ferlito A. Craniopharyngioma: a pathologic, clinical, and surgical review. Head Neck. 2012;34:1036\u201344.","journal-title":"Head Neck"},{"key":"1156_CR38","doi-asserted-by":"publisher","first-page":"1058329","DOI":"10.3389\/fonc.2022.1058329","volume":"12","author":"MK Na","year":"2022","unstructured":"Na MK, Jang B, Choi K-S, et al. Craniopharyngioma resection by endoscopic endonasal approach versus transcranial approach: a systematic review and meta-analysis of comparative studies. Front Oncol. 2022;12:1058329.","journal-title":"Front Oncol"},{"key":"1156_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13060842","author":"LF Figueredo","year":"2023","unstructured":"Figueredo LF, Mart\u00ednez AL, Suarez-Meade P, et al. Current role of endoscopic endonasal approach for craniopharyngiomas: a 10-year systematic review and meta-analysis comparison with the open transcranial approach. Brain Sci. 2023. https:\/\/doi.org\/10.3390\/brainsci13060842.","journal-title":"Brain Sci"},{"key":"1156_CR40","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/cncr.22703","volume":"109","author":"SE Combs","year":"2007","unstructured":"Combs SE, Thilmann C, Huber PE, Hoess A, Debus J, Schulz-Ertner D. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer. 2007;109:2308\u201314.","journal-title":"Cancer"},{"key":"1156_CR41","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.radonc.2006.11.005","volume":"82","author":"G Minniti","year":"2007","unstructured":"Minniti G, Saran F, Traish D, et al. Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol. 2007;82:90\u20135.","journal-title":"Radiother Oncol"},{"key":"1156_CR42","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1016\/j.ijrobp.2012.10.030","volume":"85","author":"TE Merchant","year":"2013","unstructured":"Merchant TE, Kun LE, Hua C-H, Wu S, Xiong X, Sanford RA, Boop FA. Disease control after reduced volume conformal and intensity modulated radiation therapy for childhood craniopharyngioma. Int J Radiat Oncol Biol Phys. 2013;85:e187\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1156_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.semradonc.2012.11.008","volume":"23","author":"TE Merchant","year":"2013","unstructured":"Merchant TE. Clinical controversies: proton therapy for pediatric tumors. Semin Radiat Oncol. 2013;23:97\u2013108.","journal-title":"Semin Radiat Oncol"},{"key":"1156_CR44","first-page":"482","volume":"103","author":"T Kobayashi","year":"2005","unstructured":"Kobayashi T, Kida Y, Mori Y, Hasegawa T. Long-term results of gamma knife surgery for the treatment of craniopharyngioma in 98 consecutive cases. J Neurosurg. 2005;103:482\u20138.","journal-title":"J Neurosurg"},{"key":"1156_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijrobp.2009.07.1693","volume":"78","author":"A Niranjan","year":"2010","unstructured":"Niranjan A, Kano H, Mathieu D, Kondziolka D, Flickinger JC, Lunsford LD. Radiosurgery for craniopharyngioma. Int J Radiat Oncol Biol Phys. 2010;78:64\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1156_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11060-010-0494-0","volume":"104","author":"Z Xu","year":"2011","unstructured":"Xu Z, Yen C-P, Schlesinger D, Sheehan J. Outcomes of Gamma Knife surgery for craniopharyngiomas. J Neurooncol. 2011;104:305\u201313.","journal-title":"J Neurooncol"},{"key":"1156_CR47","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/j.wneu.2019.11.111","volume":"135","author":"F Wang","year":"2020","unstructured":"Wang F, He Y, Li C, Wang Y, Zhong L. Malignant craniopharyngioma: a report of seven cases and review of the literature. World Neurosurg. 2020;135:e194\u2013201.","journal-title":"World Neurosurg"},{"key":"1156_CR48","doi-asserted-by":"crossref","unstructured":"Sofela AA, Hettige S, Curran O, Bassi S. Malignant transformation in craniopharyngiomas. Neurosurgery 2014;75:306\u201314; discussion 314.","DOI":"10.1227\/NEU.0000000000000380"},{"key":"1156_CR49","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/PAS.0b013e31802d8a96","volume":"31","author":"FJ Rodriguez","year":"2007","unstructured":"Rodriguez FJ, Scheithauer BW, Tsunoda S, Kovacs K, Vidal S, Piepgras DG. The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol. 2007;31:1020\u20138.","journal-title":"Am J Surg Pathol"},{"key":"1156_CR50","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3340\/jkns.2016.59.5.466","volume":"59","author":"IH Lee","year":"2016","unstructured":"Lee IH, Zan E, Bell WR, Burger PC, Sung H, Yousem DM. Craniopharyngiomas\u202f: radiological differentiation of two types. J Korean Neurosurg Soc. 2016;59:466\u201370.","journal-title":"J Korean Neurosurg Soc"},{"key":"1156_CR51","first-page":"77","volume":"18","author":"S Sartoretti-Schefer","year":"1997","unstructured":"Sartoretti-Schefer S, Wichmann W, Aguzzi A, Valavanis A. MR differentiation of adamantinous and squamous-papillary craniopharyngiomas. AJNR Am J Neuroradiol. 1997;18:77\u201387.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1156_CR52","first-page":"1427","volume":"17","author":"OP Eldevik","year":"1996","unstructured":"Eldevik OP, Blaivas M, Gabrielsen TO, Hald JK, Chandler WF. Craniopharyngioma: radiologic and histologic findings and recurrence. AJNR Am J Neuroradiol. 1996;17:1427\u201339.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1156_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3171\/2017.4.JNS163113","volume":"129","author":"Q Yue","year":"2018","unstructured":"Yue Q, Yu Y, Shi Z, Wang Y, Zhu W, Du Z, Yao Z, Chen L, Mao Y. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. J Neurosurg. 2018;129:27\u201334.","journal-title":"J Neurosurg"},{"key":"1156_CR54","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.32197","volume":"125","author":"TA Juratli","year":"2019","unstructured":"Juratli TA, Jones PS, Wang N, et al. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 2019;125:2910\u20134.","journal-title":"Cancer"},{"key":"1156_CR55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMe2305288","volume":"389","author":"JO Blakeley","year":"2023","unstructured":"Blakeley JO, Shannon K. Precision oncology for papillary craniopharyngioma. N Engl J Med. 2023;389:179\u201381.","journal-title":"N Engl J Med"},{"key":"1156_CR56","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-14-0776","volume":"20","author":"G Kim","year":"2014","unstructured":"Kim G, McKee AE, Ning Y-M, et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014;20:4994\u20135000.","journal-title":"Clin Cancer Res"},{"key":"1156_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427\u201330.","journal-title":"Nature"},{"key":"1156_CR58","doi-asserted-by":"crossref","unstructured":"\u2022 Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023;29:1103\u20131112. This basket trial indicated that dabrafenib combined with trametinib shows promise in the treatment of various BRAFV600E-mutated advanced rare cancers.","DOI":"10.1038\/s41591-023-02321-8"},{"key":"1156_CR59","doi-asserted-by":"crossref","unstructured":"Jouanneau E, Raverot G. Adult craniopharyngiomas: differences and lessons from paediatrics. Springer Nature; 2020.","DOI":"10.1007\/978-3-030-41176-3"},{"key":"1156_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv310","author":"PK Brastianos","year":"2016","unstructured":"Brastianos PK, Shankar GM, Gill CM, et al. Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. 2016. https:\/\/doi.org\/10.1093\/jnci\/djv310.","journal-title":"J Natl Cancer Inst"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-023-01156-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-023-01156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T03:11:11Z","timestamp":1708139471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-023-01156-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1007\/s11864-023-01156-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"22 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"DG and SS have no conflicts of interest or disclosures to report. PKB has consulted for Angiochem, Merck, Genentech-Roche, Lilly, Tesaro, ElevateBio, Dantari, Voyager Therapeutics, SK Life Sciences, Pfizer, ACI, Sintetica, Kazia, MPM, CraniUS, Axiom and InCephalo, serves on the Scientific Advisory Board for Kazia, has received grant\/research support (to MGH) from Merck, Lilly, Mirati, BMS and Kinnate, and speaker\u2019s honoraria from Merck, Genentech-Roche, Lilly and Medscape.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}